SCHEMBL1637655

SCHEMBL1637655

Fc1cc2sc(Br)nc2cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.38
AKR1B1 P15121 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.32
ALDH1A1 P00352 3/20 0.32
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
PKM P14618 2/20 0.32
HPGD P15428 2/20 0.32
TP53 P04637 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ILK Q13418 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GAA P10253 3/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
POLB P06746 1/20 0.31
HTT P42858 1/20 0.31
KMT2A Q03164 1/20 0.31
ATM Q13315 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18791159 0.84 MMP1 (0.38) MAPTAKR1B1SMN1; SMN2ALDH1A1NPC1
SCHEMBL3091345 0.84 ILK (0.38) MAPTAKR1B1SMN1; SMN2ALDH1A1NPC1
SCHEMBL18791344 0.82 KMT2A (0.40) MAPTAKR1B1SMN1; SMN2ALDH1A1NPC1
SCHEMBL1638626 0.79 AXL (0.53) MAPTSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL21882016 0.79 SMN1; SMN2 (0.59) MAPTSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL21882018 0.79 MAPT (0.37) MAPTAKR1B1SMN1; SMN2ALDH1A1NPC1
SCHEMBL18315218 0.76 RAB9A (0.46) MAPTSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL17839736 0.76 ILK (0.49) MAPTSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL24225514 0.75 NPC1 (0.65) MAPTAKR1B1SMN1; SMN2ALDH1A1NPC1
SCHEMBL10218875 0.74 KMT2A (0.40) MAPTAKR1B1SMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098292-A1 New Compounds Useful for Treating CNS Disorders ASTRAZENECA AB (SE) 2011-04-28 US disclosed
CN-1980922-A New compounds useful for treating CNS disorders ASTRAZENECA AB (SE) 2007-06-13 CN disclosed
EP-1765815-A2 NEW COMPOUNDS USEFUL FOR TREATING CNS DISORDERS AstraZeneca AB (SE) 2007-03-28 EP disclosed
WO-2006004507-A2 NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS ASTRAZENECA AB (SE) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098292-A1 New Compounds Useful for Treating CNS Disorders SLC18A2, PMP22, GAP43 MAPT 96/4885AKR1B1 1246/4885SMN1; SMN2 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.